This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2006, p. 2530-2532, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00238-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Activities of Ceftobiprole and Other ß-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x

Todd A. Davies,* Wenchi Shang, and Karen Bush

Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey

Received 24 February 2006/ Returned for modification 12 April 2006/ Accepted 20 April 2006

The activities of ceftobiprole and other ß-lactams were examined with 30 Streptococcus pneumoniae isolates containing multiple pbp1a, pbp2b, and pbp2x mutations. The highest ceftobiprole MIC was 1 µg/ml, while the comparator MICs were 16 to 64 µg/ml. Fifty percent inhibitory concentrations for penicillin-binding protein 2x were 0.5 µg/ml (ceftobiprole) and 4 µg/ml (ceftriaxone) in a penicillin- and ceftriaxone-resistant isolate.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research & Development, LLC, Room B225, 1000 Route 202, Raritan, NJ 08869. Phone: (908) 707-3465. Fax: (908) 707-3501. E-mail: tdavies{at}prdus.jnj.com.

Antimicrobial Agents and Chemotherapy, July 2006, p. 2530-2532, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00238-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Anderson, S. D, Gums, J. G (2008). Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin. The Annals of Pharmacotherapy 42: 806-816 [Abstract] [Full Text]  
  • Davies, T. A., Shang, W., Bush, K., Flamm, R. K. (2008). Activity of doripenem and comparator {beta}-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. J Antimicrob Chemother 61: 751-753 [Full Text]  
  • Queenan, A. M., Shang, W., Kania, M., Page, M. G. P., Bush, K. (2007). Interactions of Ceftobiprole with {beta}-Lactamases from Molecular Classes A to D. Antimicrob. Agents Chemother. 51: 3089-3095 [Abstract] [Full Text]  
  • Davies, T. A., Page, M. G. P., Shang, W., Andrew, T., Kania, M., Bush, K. (2007). Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 2621-2624 [Abstract] [Full Text]  
  • Arias, C. A., Singh, K. V., Panesso, D., Murray, B. E. (2007). Time-Kill and Synergism Studies of Ceftobiprole against Enterococcus faecalis, Including {beta}-Lactamase-Producing and Vancomycin-Resistant Isolates. Antimicrob. Agents Chemother. 51: 2043-2047 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»